Related Experiment Videos
A phenomenologic assessment of relapsing MS patients' experiences during treatment with interferon beta-1a
1Buffalo General Hospital Department of Neurology, University at Buffalo, State University of New York, School of Medicine and Biomedical Science, 100 High Street, Buffalo, NY, USA.
Abstract:
The purpose of this study was to describe the experiences of patients with relapsing multiple sclerosis (MS) who are being treated with interferon beta-1a. MS patients often experience fear and uncertainty about their future and derive benefit from understanding their diagnosis as well as learning about their anticipated disease course. Interferon beta-1a treatment can delay the accumulation of physical disability that naturally occurs over time in patients with untreated relapsing MS and thus offer hope for their future. However, patients may be afraid to start interferon beta-1a because they do not know what to expect. To answer the question, "What is the patient's experience on interferon beta-1a," we used Heideggerian phenomenologic and Colaizzi's qualitative data analysis techniques to interpret serial interviews of 15 patients with relapsing MS. Interviews were audiotaped, transcribed verbatim, and analyzed by using the Martin qualitative data analysis computer program. The theme clusters that emerged were learning, feelings, adaptation, and interferon beta-1a issues. An exhaustive description of the phenomena that were derived illustrates the patients' process of learning about their illness and adapting to changes in their lives. Starting a new treatment requires coping and challenges use of resources. Social support is vital to patients, particularly those who have difficulty injecting themselves. Most of the patients expressed a sense of improvement in their condition since starting on interferon beta-1a treatment and considered it crucial to their hope for the future.
Insights
Patients treated with interferon beta-1a for relapsing multiple sclerosis (MS) report positive experiences. This treatment offers hope by delaying disability and improving their condition, aiding adaptation to illness.
Area of Science:
- Neurology
- Immunology
- Qualitative Health Research
Background:
- Relapsing multiple sclerosis (MS) presents significant challenges, including fear and uncertainty regarding disease progression.
- Understanding the patient experience with disease-modifying therapies is crucial for effective management.
- Interferon beta-1a is a treatment option for relapsing MS that can delay physical disability accumulation.
Purpose of the Study:
- To explore and describe the lived experiences of patients with relapsing MS undergoing treatment with interferon beta-1a.
- To understand patient perspectives on managing their condition and adapting to treatment.
- To identify key themes and challenges associated with initiating and adhering to interferon beta-1a therapy.
Main Methods:
- Qualitative study employing Heideggerian phenomenology and Colaizzi's data analysis techniques.
- Serial interviews were conducted with 15 patients diagnosed with relapsing MS.
- Interviews were audio-recorded, transcribed verbatim, and analyzed using the Martin qualitative data analysis computer program.
Main Results:
- Emergent themes included patient learning about MS, emotional responses, adaptation processes, and specific issues related to interferon beta-1a.
- Patients described a process of learning about their illness and adapting to life changes.
- Social support was identified as vital, especially for patients experiencing difficulties with self-injection.
Conclusions:
- Most patients reported a sense of improvement and viewed interferon beta-1a treatment as essential for maintaining hope.
- Effective coping strategies and resource utilization are important when starting new treatments like interferon beta-1a.
- Qualitative insights into patient experiences can inform healthcare providers and support systems for MS patients on interferon beta-1a.